ReviewInternational journal of molecular medicine2025
PANoptosis: A novel therapeutic target in kidney disease (Review).
Review in International journal of molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Immune molecular mechanisms of PANoptosis in sepsis-induced acute kidney injury.Inflammation and regeneration · 2026Review
- The Role of Traditional Chinese Medicine in Acute Lung Injury: Targeting Programmed Cell Death.Drug design, development and therapy · 2026Review
- Recent advances in PANoptosis research in kidney disease: mechanistic networks, pathological roles, and potential intervention strategies.Frontiers in immunology · 2026Review
- Identification of PANoptosis hub genes driving immune activation and tubulointerstitial injury in diabetic kidney disease by integrative bioinformatics and machine learning.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global prevalence of kidney diseases continues to rise annually, posing a serious public health challenge, and notably contributing to morbidity and mortality rates worldwide. In affected individuals, kidney function progressively declines, ultimately resulting in renal failure. Therefore, elucidating the pathophysiological mechanisms underlying kidney diseases and identifying novel therapeutic targets is of paramount importance. Among these, the regulation of cell death pathways has emerged as a pivotal factor in disease progression. PANoptosis, a recently characterized form of programmed cell death, is activated by diverse stimuli, and involves the integrated activation of pyroptosis, apoptosis and necroptosis, coordinated through the PANoptosome complex. Increasing evidence has suggested that PANoptosis serves an important role in the development of kidney diseases, and further investigation into its regulatory mechanisms may provide valuable insights into disease modulation. The present review summarizes current knowledge regarding the mechanisms of PANoptosis and its involvement in various kidney diseases, offering perspectives for future diagnostic and therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.